Cargando…

Rapidly Progressive Felty Syndrome After Sudden Discontinuation of Methotrexate: A Case Report and Review of Literature

Felty syndrome (FS) is a disorder that develops after a long history of erosive rheumatoid arthritis and presents with splenomegaly and neutropenia. In addition to joint deformities, FS causes a variety of extra-articular manifestations such as vasculitis, skin lesions, and lymphadenopathy. FS is al...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamsho, Suaad, Alannouf, Isam, Ashour, Anas A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449881/
https://www.ncbi.nlm.nih.gov/pubmed/36091198
http://dx.doi.org/10.2147/IMCRJ.S365004
_version_ 1784784399505555456
author Hamsho, Suaad
Alannouf, Isam
Ashour, Anas A
author_facet Hamsho, Suaad
Alannouf, Isam
Ashour, Anas A
author_sort Hamsho, Suaad
collection PubMed
description Felty syndrome (FS) is a disorder that develops after a long history of erosive rheumatoid arthritis and presents with splenomegaly and neutropenia. In addition to joint deformities, FS causes a variety of extra-articular manifestations such as vasculitis, skin lesions, and lymphadenopathy. FS is also reported to cause non-cirrhotic portal hypertension which may result in variceal bleeding. FS is usually treated by disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate. Herein, we report a case of rapidly deteriorating FS and a severe relapsing neutropenia only a few weeks after discontinuation of methotrexate and other available DMARDs. The patient presented with a fever and a multi-drug resistant gangrenous ulcer consistent with ecthyma gangrenosum. The patient was also found to have hepatosplenomegaly and portal hypertension. The case was managed with antibiotics and symptomatic treatments only as DMARDs were either unavailable or not affordable by the patient. However, the patient's condition did not improve. This case highlights that DMARDs are considered an essential part of preventing infections due to FS neutropenia. Patients with FS should continue DMARDs for life to avoid the relapse of their condition.
format Online
Article
Text
id pubmed-9449881
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-94498812022-09-08 Rapidly Progressive Felty Syndrome After Sudden Discontinuation of Methotrexate: A Case Report and Review of Literature Hamsho, Suaad Alannouf, Isam Ashour, Anas A Int Med Case Rep J Case Report Felty syndrome (FS) is a disorder that develops after a long history of erosive rheumatoid arthritis and presents with splenomegaly and neutropenia. In addition to joint deformities, FS causes a variety of extra-articular manifestations such as vasculitis, skin lesions, and lymphadenopathy. FS is also reported to cause non-cirrhotic portal hypertension which may result in variceal bleeding. FS is usually treated by disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate. Herein, we report a case of rapidly deteriorating FS and a severe relapsing neutropenia only a few weeks after discontinuation of methotrexate and other available DMARDs. The patient presented with a fever and a multi-drug resistant gangrenous ulcer consistent with ecthyma gangrenosum. The patient was also found to have hepatosplenomegaly and portal hypertension. The case was managed with antibiotics and symptomatic treatments only as DMARDs were either unavailable or not affordable by the patient. However, the patient's condition did not improve. This case highlights that DMARDs are considered an essential part of preventing infections due to FS neutropenia. Patients with FS should continue DMARDs for life to avoid the relapse of their condition. Dove 2022-09-02 /pmc/articles/PMC9449881/ /pubmed/36091198 http://dx.doi.org/10.2147/IMCRJ.S365004 Text en © 2022 Hamsho et al. https://creativecommons.org/licenses/by/4.0/This work is published by Dove Medical Press Limited, and licensed under a Creative Commons Attribution License. The full terms of the License are available at http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Case Report
Hamsho, Suaad
Alannouf, Isam
Ashour, Anas A
Rapidly Progressive Felty Syndrome After Sudden Discontinuation of Methotrexate: A Case Report and Review of Literature
title Rapidly Progressive Felty Syndrome After Sudden Discontinuation of Methotrexate: A Case Report and Review of Literature
title_full Rapidly Progressive Felty Syndrome After Sudden Discontinuation of Methotrexate: A Case Report and Review of Literature
title_fullStr Rapidly Progressive Felty Syndrome After Sudden Discontinuation of Methotrexate: A Case Report and Review of Literature
title_full_unstemmed Rapidly Progressive Felty Syndrome After Sudden Discontinuation of Methotrexate: A Case Report and Review of Literature
title_short Rapidly Progressive Felty Syndrome After Sudden Discontinuation of Methotrexate: A Case Report and Review of Literature
title_sort rapidly progressive felty syndrome after sudden discontinuation of methotrexate: a case report and review of literature
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449881/
https://www.ncbi.nlm.nih.gov/pubmed/36091198
http://dx.doi.org/10.2147/IMCRJ.S365004
work_keys_str_mv AT hamshosuaad rapidlyprogressivefeltysyndromeaftersuddendiscontinuationofmethotrexateacasereportandreviewofliterature
AT alannoufisam rapidlyprogressivefeltysyndromeaftersuddendiscontinuationofmethotrexateacasereportandreviewofliterature
AT ashouranasa rapidlyprogressivefeltysyndromeaftersuddendiscontinuationofmethotrexateacasereportandreviewofliterature